Mankind Pharma Licenses Two Insulin Products, Expands Diabetes Portfolio
Mumbai: Mankind Pharma has entered into an exclusive in-licensing and marketing agreement with China-based Chongqing Chenan Biopharmaceutical for two insulin products in India. The agreement covers Insulin Degludec and a combination of Insulin Degludec and Insulin Aspart. Mankind Pharma will commercialise both injectable treatments in the Indian market. Diabetes portfolio expands The partnership…
Mankind Pharma has secured an exclusive in-licensing and marketing agreement with China-based Chongqing Chenan Biopharmaceutical to bring two insulin products to the Indian market. The deal includes Insulin Degludec and a combination of Insulin Degludec with Insulin Aspart. This partnership will bolster Mankind Pharma's diabetes portfolio and strengthen its position in India's growing diabetes-care market.
The long-acting insulin analogue, Insulin Degludec, aids in managing blood sugar levels alone or when paired with rapid-acting Insulin Aspart. This collaboration aligns with Mankind Pharma's strategy of increasing its presence in chronic therapies, including diabetes. Atish Majumdar, Senior President for Sales and Marketing at Mankind Pharma, highlighted China as a burgeoning hub for innovative biopharmaceutical assets, emphasizing the company's commitment to expanding its in-licensing pipeline from China.
The agreement is anticipated to enhance patient access to advanced therapies while reinforcing Mankind Pharma's standing in the injectable diabetes segment. With a nationwide field force of over 18,500 professionals and a presence in more than five lakh doctors, Mankind Pharma's comprehensive infrastructure, comprising 32 manufacturing facilities and seven research and development centers, supports the rollout of these advanced therapies.
Written by urgent.news from Free Press Journal's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
